Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections

Southern Medical Journal

Volumn 90, Issue 12, 1997, Pages 1193-1200

  Nichols, Ronald Lee ^a   Smith, Jeffrey W ^a   Gentry, Layne O ^b   Gezon, John ^c   Campbell, Theresa ^d   Sokol, Paul ^d   Williams, R Rex ^d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c Holy Cross Hospital   (United States)

^d R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; TREATMENT OUTCOME;

EID: 0030660499     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199712000-00006     Document Type: Article

References (24)

1. Von Rosenstiel N, Adam D: Quinolone antibacterials. Drugs 1994; 47:872-901
2. Cruciani M, Bassetti D: The fluoroquinolones as treatment for infections caused by gram-positive bacteria. J Antimicrob Chemother 1994; 33:403-417
3. Gentry LO: Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother 1991; 28(suppl C):97-110
4. Gentry LO: Therapy with newer oral b-lactam and quinolone agents for infections of the skin and skin structures: a review. Clin Infect Dis 1992; 14:285-297
5. Fu KP, Lafredo SC, Foleno B, et al: In vitro and in vivo antibacterial activities of levofloxacin (1-ofloxacin), an optically active isomer of ofloxacin. Antimicrob Agents Chemother 1992; 36:860-866
6. Davis R, Bryson HM: Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47:677-700
7. Foleno BD, Lafredo SC, Fu KP: In vitro activity of levofloxacin, ofloxacin and other quinolones against coagulase-negative staphylococci. Chemotherapy 1993; 39:120-123
8. Fujimoto T, Mitsuhashi S: In vitro activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy 1990; 36:268-276
9. Peterson LR, Cooper I, Willard KE, et al: Activity of 21 antimicrobial agents including 1-ofloxacin against quinolone-sensitivc and -resistant, and methicillin-sensitive and -resistant Staphylococcus aureus. Chemotherapy 1994; 42:21-25
10. Dholakia N, Rolston KVI, Ho DH, et al: Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 1994; 38:848-852
11. Marshall SA, Jones RN: The in vitro activity of DU-6859a, a new fluoropropyl quinolone. Antimicrob Agents Chemother 1993; 37:2747-2753
12. Chien S-C, Rogge MC, Gisclon LG, et al: Pharmacokinetic profile of levofloxacin following once daily 500-mg oral or intravenous doses. Antimicrob Agents Chemother 1997 (In press)
13. Flor SC, Rogge MC, Chow AT: Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Antimicrob Agents Chemother 1993;37:1468-1472
14. Yuk JH, Nightingale CH, Quintiliani R, et al: Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother 1991; 35:384-386
15. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests: M2-A4. Villanova, Pa, National Committee for Clinical Laboratory Standards, 1990
16. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: M7-A2. Villanova, Pa, National Committee for Clinical Laboratory Standards, 1990
17. Pfaller MA, Barry AL, Fuchs PC: Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests. J Clin Microbiol 1993; 31:1924-1926
18. Mulligan ME, Ruane PJ, Johnson L, et al: Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med 1987; 82(suppl 4A):215-219
19. Piercy EA, Barbaro D, Luby JP, et al: Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 1989; 33:128-130
20. Smith SM, Eng RHK, Tecson-Tumang F: Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother 1989; 33:181-184
21. Fass RJ, Plouffe JF, Russell JA: Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med 1989; 87(suppl 5A):164S-168S
22. Gentry LO, Koshdel A: Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. Am J Med 1989; 87(suppl A):132S-135S
23. Data on file: Raritan, NJ, RW Johnson Pharmaceutical Research Institute
24. Nicodemo AC, Robledo JA, Jasovich A, et al: A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs ciprofloxacin in the treatment of skin and skin structure infections (Poster LM4). Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La, September 15-18, 1996